The research group ofUniversity of Pittsburgh for many years he has been studying vaccines to fight coronaviruses, the first dates back to 2003 where the spike protein as a target for coronavirus vaccines. With the outbreak of the pandemic, the team, also on the basis of previous studies, immediately set to work to quickly develop the vaccine capable of fighting the SarsCoV-2 virus. The study was published in the journal The Lancet.
Is called PittCoVacc, it is a vaccine-patch and differs from traditional vaccines for the technology used, the storage, the method of administration, but it has not been tested on humans ...Why?
What are the features and benefits? Where are we at? Is PittCoVacc also effective against variants?
Professor Andrea Gambotto explains it in the video interview